Light To Guide Our Feet
Light To Guide Our Feet

Menu

Collapse

Search Result

Collapse

Announcement

Collapse
No announcement yet.

What's Going On

Collapse

There are currently 137 users online. 35 members and 102 guests.

Most users ever online was 3,930 at 07:07 PM on 04-20-2019.

30 results in 0.0055 seconds.
Keywords
Members
Tags
approves x
  •  

  • U.S. Food and Drug Administration Approves First Drug to Treat Rare Metabolic Disorder

    U.S. Food and Drug Administration Approves First Drug to Treat Rare Metabolic Disorder | site |


    Approval is for primary hyperoxaluria type 1, which causes recurrent kidney stones and loss of kidney function


    (Information contained in U.S. Food and Drug Administration [FDA] press release: November 23, 2020) Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. This approval is a cumulation of the work of experts and community members coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative. “The approval of Oxlumo represents a great triumph of community involvement to address a rare disease. It is a result of input from patients, treating physicians, experts and sponsors at a patient-focused drug development meeting and through other collaborative efforts,” said Norman Stockbridge, M.D., Ph.D., director of the ...
    See more | Go to post

  • FDA Approves First Intratumoral Injection to Treat Non-Metastatic Mast Cell Tumors in Dogs

    U.S. Food and Drug Administration Approves First Intratumoral Injection to Treat Non-Metastatic Mast Cell Tumors in Dogs| site |


    (November 16, 2020) - - Today the U.S. Food and Drug Administration (FDA) published the following information: Today, the U.S. Food and Drug Administration approved Stelfonta (tigilanol tiglate injection) to treat dogs with non-metastatic, skin-based (cutaneous) mast cell tumors (MCTs). The FDA is also approving Stelfonta to treat non-metastatic MCTs located under the dog’s skin (subcutaneous), in particular areas of a dog’s leg. Stelfonta is injected directly into the MCT (intratumoral injection). Stelfonta works by activating a protein that spreads throughout the treated tumor, which disintegrates tumor cells. “This is the first approval for an intratumoral injection to treat non-metastatic mast cell tumors in dogs,” said Steven M. Solomon, D.V.M., M.P.H., director of the FDA’s Center for Veterinary Medicine. “This appro...
    See more | Go to post

  • Federal Reserve Board approves Fee Schedule for Federal Reserve Bank Priced Services

    Federal Reserve Board approves Fee Schedule for Federal Reserve Bank Priced Services | site |


    (November 10, 2020) - - Today the Board of Governors of the Federal Reserve System published the following information: The Federal Reserve Board on Tuesday announced the approval of fee schedules, effective January 4, 2021, for payment services the Federal Reserve Banks provide to depository institutions (priced services). The Reserve Banks project that they will recover 98.7 percent of their priced services costs in 2021. The Reserve Banks will maintain the current schedule of prices for payment services provided to depository institutions (priced services) in 2021, with the exception of a modification to the Check Services participation fee. While the Reserve Banks do not expect to recover fully actual and imputed expenses, including profit that would have been earned if a private-sector firm provided the services, in 2021, they do expect to recover fully expenses over the...
    See more | Go to post

  • FDA Approves First Treatment for COVID-19

    FDA Approves First Treatment for COVID-19

    U.S. Food and Drug Administration Approves First Treatment for COVID-19 | site |




    (October 22, 2020) - - Today, October 22, 2020, the U.S. Food and Drug Administration (FDA) published the following information:

    Today, the U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. Veklury is the first treatment for COVID-19 to receive FDA approval. This approval does not include the entire population that had been authorized to use Veklury under an Emergency Use Authorization (EUA) originally issued on May 1, 2020. In order to ensure continued access to the pediatric population previously covered und
    ...
    See more | Go to post

  • U.S. Food and Drug Administration Approves First Treatment for Ebola Virus

    U.S. Food and Drug Administration Approves First Treatment for Ebola Virus

    U.S. Food and Drug Administration Approves First Treatment for Ebola Virus | site |


    (October 14, 2020) - - The U.S. Food and Drug Administration (FDA) published today, October 14, 2020, the following information:

    Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.

    “Today’s action demonstrates the FDA’s ongoing commitment to responding to public health threats—both domestically and abroad—on the basis of science and data,” said FDA Commissioner Stephen M. Hahn, M.D. “This approval was made possible because of our steadfast dedication to facilitate the development of safe and effective treatments for infectious diseases as part of our vital public health mission.”

    Zaire ebolavirus, commonly known as Ebola virus, is one
    ...
    See more | Go to post

  • U.S. Education Secretary DeVos Approves Second Wave of Perkins Career and Technical Education State Plans

    U.S. Education Secretary DeVos Approves Second Wave of Perkins Career and Technical Education State Plans| site |



    Plans detail how states will use federal investment to offer students multiple pathways to success


    (May 29, 2020) - - Today (May 29, 2020), the U.S. Department of Education published the following information: WASHINGTON — U.S. Secretary of Education Betsy DeVos announced today the Department of Education has approved nine additional career and technical education (CTE) state plans. Georgia, Iowa, Michigan, Montana, North Dakota, Oregon, South Dakota, Vermont, and Wyoming are the latest states to have their CTE plans approved under the new, bipartisan Strengthening Career and Technical Education for the 21stCentury Act (Perkins V), which was signed into law by President Donald J. Trump on July 31, 2018. "Thanks to the president's leadership, the new career and technical education law gives local leaders the flexibility to make...
    See more | Go to post

  • U.S. Education Secretary DeVos Approves First Wave of Perkins Career and Technical Education State Plans

    U.S. Education Secretary DeVos Approves First Wave of Perkins Career and Technical Education State Plans| site |



    Plans detail how states will use federal investment to offer students multiple pathways to success


    (May 22, 2020) - - Today, the U.S. Department of Education published the following information: WASHINGTON — U.S. Secretary of Education Betsy DeVos announced today the Department of Education has approved six career and technical education (CTE) state plans. Hawaii, Illinois, Maine, Maryland, Massachusetts, and New Hampshire are the first six states to have their CTE plans approved under the new, bipartisan Strengthening Career and Technical Education for the 21st Century Act (Perkins V), which was signed into law by President Donald J. Trump on July 31, 2018. "Thanks to the President's leadership, the new career and technical education law gives local leaders the flexibility to make investments in the highest impact areas of...
    See more | Go to post

  • Federal Communications Commission Approves Seventh Set of COVID-19 Telehealth Program Applications

    Federal Communications Commission Approves Seventh Set of COVID-19 Telehealth Program Applications | site |


    Commission Continues Approving Telehealth Funding During Coronavirus Pandemic, Surpasses $50 Million in Total Funding


    (May 20, 2020) - - Today, the Federal Communications Commission (FCC) published the following information: WASHINGTON, May 20, 2020—The Federal Communications Commission’s Wireline Competition Bureau today approved an additional 43 funding applications for the COVID-19 Telehealth Program. Health care providers in both urban and rural areas of the country will use this $16.87 million in funding to provide telehealth services during the coronavirus pandemic. To date, the FCC’s COVID-19 Telehealth Program, which was authorized by the CARES Act, has approved funding for 132 health care providers in 33 states plus Washington, DC for a total of just over $50 million in funding. Below is a list of health care providers that wer...
    See more | Go to post

  • FDA Approves First Treatment for Group of Progressive Interstitial Lung Diseases

    U.S. Food and Drug Administration Approves First Treatment for Group of Progressive Interstitial Lung Diseases| site |



    (March 9, 2020) - - Today, the U.S. Food and Drug Administration (FDA) published the following information:

    The U.S. Food and Drug Administration today approved Ofev (nintedanib) oral capsules to treat patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait). It is the first FDA-approved treatment for this group of fibrosing lung diseases that worsen over time.

    “The FDA continues to encourage the development of therapies for patients with limited or no treatment options,” said Banu Karimi-Shah, M.D., acting deputy director of the Division of Pulmonary, Allergy, and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research. “Today’s approval helps to fulfill an unmet treatment need, as patients with these life-threatening lung diseases
    ...
    See more | Go to post

  • Federal Reserve Board Approves Rule to Simplify its Capital Rules for Large Banks, Preserving the Strong Capital Requirements Already in Place

    Federal Reserve Board Approves Rule to Simplify its Capital Rules for Large Banks, Preserving the Strong Capital Requirements Already in Place| site |




    (March 4, 2020) - - Today, the Board of Governors of the Federal Reserve System published the following information: The Federal Reserve Board on Wednesday approved a rule to simplify its capital rules for large banks, preserving the strong capital requirements already in place. The "stress capital buffer," or SCB, integrates the Board's stress test results with its non-stress capital requirements. As a result, required capital levels for each firm would more closely match its risk profile and likely losses as measured via the Board's stress tests. The rule is broadly similar to the proposal from April 2018, with a few changes in response to comments. "The stress capital buffer materially simplifies the post-crisis capital framework for banks, while maintaining the strong capital requirements that ar...
    See more | Go to post

  • Federal Reserve Board approves Fee Schedule for Federal Reserve Bank Priced Services

    Federal Reserve Board approves Fee Schedule for Federal Reserve Bank Priced Services | site |



    (November 27, 2019) - - Today (November 27, 2019), the Board of Governors of the Federal Reserve System published the following information: The Federal Reserve Board on Wednesday announced the approval of fee schedules, effective January 2, 2020, for payment services the Federal Reserve Banks provide to depository institutions (priced services). The Reserve Banks project that they will recover 100.2 percent of their priced services costs in 2020. The Reserve Banks expect to fully recover actual and imputed expenses, including profit that would have been earned if a private-sector firm provided the services. Overall, the Reserve Banks estimate that the price changes will result in a 2.4 percent average price increase. The Reserve Banks estimate that the price changes will result in a 3.3 percent average price increase for Check Services customers; a 3.7 percent average p
    ...
    See more | Go to post

  • FDA Approves First Targeted Therapy to Treat Patients with Painful Complication of Sickle Cell Disease

    U.S. Food and Drug Administration Approves First Targeted Therapy to Treat Patients with Painful Complication of Sickle Cell Disease | site |



    (November 15, 2019) - - The U.S. Food and Drug Administration (FDA) published (today) the following information: Today, the U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells – for patients age 16 years and older. “Hope has never been higher for people living with sickle cell disease and their families and supporters, with a pipeline of new treatments on the horizon, like the one being approved today, and several initiatives underway to better utilize current tools in the battle against the painful and deadly blood disorder,” said Acting FDA Commissioner Adm. Brett P. Giroir, M.D. “The opportunity
    ...
    See more | Go to post

  • U.S. Department of the Interior Approves Long-Awaited First Oil Production Facility in Federal Waters Offshore Alaska

    U.S. Department of the Interior Approves Long-Awaited First Oil Production Facility in Federal Waters Offshore Alaska



    Washington, DC - - (October 24, 2018) - - U.S. Secretary of the Interior Ryan Zinke today announced a long-awaited development for oil and gas energy production offshore the state of Alaska. Interior’s Bureau of Ocean Energy Management (BOEM) issued conditional approval to Hilcorp Alaska LLC for its Liberty Project oil and gas development and production plan. If developed, the facility would be the first oil and gas production facility in federal waters off Alaska.




    View of an operational gravel island rig offshore Alaska.
    (Photo by Bureau of Safety and Environmental Enforcement)





    Hilcorp proposes to build a nine-acre artificial gravel island in the shallow waters of the Beaufort Sea, about...
    See more | Go to post

  • U.S. Food and Drug Administration Approves New DNA-based Test to Determine Blood Compatibility

    U.S. Food and Drug Administration Approves New DNA-based Test to Determine Blood Compatibility



    Test is first approved to report genotypes as final results


    (October 11, 2018) - - The U.S. Food and Drug Administration today approved ID CORE XT, a molecular-based assay used in blood transfusion medicine to help determine blood compatibility. The assay can be used to determine blood donor and patient non-ABO red blood cell (RBC) types. ID CORE XT is the second molecular assay approved for use in transfusion medicine, and the first to report genotypes as final results. “The approval of the ID CORE XT Test can streamline blood compatibility testing and provides an additional alternative to testing blood with antisera,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “We know that DNA testing holds great promise – to prov
    ...
    See more | Go to post

  • Federal Reserve Board Approves Action by the Boards of Directors of the Federal Reserve Bank of New York and Minneapolis

    Federal Reserve Board Approves Action by the Boards of Directors of the Federal Reserve Bank of New York and Minneapolis




    (September 27, 2018) - - The Federal Reserve Board has approved actions on Thursday by the Boards of Directors of the Federal Reserve Banks of New York and Minneapolis, increasing the discount rate (the primary credit rate) at the Banks from 2-1/2 percent to 2-3/4 percent, effective immediately.




    Source: Board of Governors of the Federal Reserve Bank...
    See more | Go to post

Menu

Collapse

Trending

Collapse

  • Staff Reporter 1
    U.S. Food and Drug Administration Approves First Drug to Treat Rare Metabolic Disorder
    by Staff Reporter 1
    U.S. Food and Drug Administration Approves First Drug to Treat Rare Metabolic Disorder | site |


    Approval is for primary hyperoxaluria type 1, which causes recurrent kidney stones and loss of kidney function


    (Information contained in U.S. Food and Drug Administration [FDA] press release: November 23, 2020) Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. This approval is a cumulation of the work of experts and community members coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative. “The approval of Oxlumo represents a great triumph of community involvement to address a rare disease. It is a result of input from patients, treating physicians, experts and sponsors at a patient-focused drug development meeting and through other collaborative efforts,” said Norman Stockbridge, M.D., Ph.D., director of the ...
    11-24-2020, 11:35 AM
  • Staff Reporter 1
    FDA Approves First Intratumoral Injection to Treat Non-Metastatic Mast Cell Tumors in Dogs
    by Staff Reporter 1
    U.S. Food and Drug Administration Approves First Intratumoral Injection to Treat Non-Metastatic Mast Cell Tumors in Dogs| site |


    (November 16, 2020) - - Today the U.S. Food and Drug Administration (FDA) published the following information: Today, the U.S. Food and Drug Administration approved Stelfonta (tigilanol tiglate injection) to treat dogs with non-metastatic, skin-based (cutaneous) mast cell tumors (MCTs). The FDA is also approving Stelfonta to treat non-metastatic MCTs located under the dog’s skin (subcutaneous), in particular areas of a dog’s leg. Stelfonta is injected directly into the MCT (intratumoral injection). Stelfonta works by activating a protein that spreads throughout the treated tumor, which disintegrates tumor cells. “This is the first approval for an intratumoral injection to treat non-metastatic mast cell tumors in dogs,” said Steven M. Solomon, D.V.M., M.P.H., director of the FDA’s Center for Veterinary Medicine. “This appro...
    11-16-2020, 08:35 PM
  • Staff Reporter 1
    Federal Reserve Board approves Fee Schedule for Federal Reserve Bank Priced Services
    by Staff Reporter 1
    Federal Reserve Board approves Fee Schedule for Federal Reserve Bank Priced Services | site |


    (November 10, 2020) - - Today the Board of Governors of the Federal Reserve System published the following information: The Federal Reserve Board on Tuesday announced the approval of fee schedules, effective January 4, 2021, for payment services the Federal Reserve Banks provide to depository institutions (priced services). The Reserve Banks project that they will recover 98.7 percent of their priced services costs in 2021. The Reserve Banks will maintain the current schedule of prices for payment services provided to depository institutions (priced services) in 2021, with the exception of a modification to the Check Services participation fee. While the Reserve Banks do not expect to recover fully actual and imputed expenses, including profit that would have been earned if a private-sector firm provided the services, in 2021, they do expect to recover fully expenses over the...
    11-11-2020, 01:48 AM
  • Staff Reporter 1
    FDA Approves First Treatment for COVID-19
    by Staff Reporter 1
    U.S. Food and Drug Administration Approves First Treatment for COVID-19 | site |




    (October 22, 2020) - - Today, October 22, 2020, the U.S. Food and Drug Administration (FDA) published the following information:

    Today, the U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. Veklury is the first treatment for COVID-19 to receive FDA approval. This approval does not include the entire population that had been authorized to use Veklury under an Emergency Use Authorization (EUA) originally issued on May 1, 2020. In order to ensure continued access to the pediatric population previously covered und
    ...
    10-23-2020, 11:22 AM
  • Staff Reporter 1
    U.S. Food and Drug Administration Approves First Treatment for Ebola Virus
    by Staff Reporter 1
    U.S. Food and Drug Administration Approves First Treatment for Ebola Virus | site |


    (October 14, 2020) - - The U.S. Food and Drug Administration (FDA) published today, October 14, 2020, the following information:

    Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.

    “Today’s action demonstrates the FDA’s ongoing commitment to responding to public health threats—both domestically and abroad—on the basis of science and data,” said FDA Commissioner Stephen M. Hahn, M.D. “This approval was made possible because of our steadfast dedication to facilitate the development of safe and effective treatments for infectious diseases as part of our vital public health mission.”

    Zaire ebolavirus, commonly known as Ebola virus, is one
    ...
    10-15-2020, 07:13 AM

Menu

Collapse

Menu

Collapse

Working...
X